IGV-001 cellular immunotherapy for newly diagnosed glioblastoma: overcoming the logistic challenge.

ABSTRACT:

Background

IGV-001 is a type of cellular immunotherapy currently being investigated for treating glioblastoma (NCT04485949). It uses the patient's tumor to elicit an autologous immune response.

Methods

The process involves (i) craniotomy for maximum safe resection of the glioblastoma, (ii) ex-vivo treatment of the tumor with an anti-sense oligodeoxynucleotide against insulin-like growth factor 1 receptor followed by irradiation, (iii) placement of the treated tumor in multiple bio-diffusion chambers, which are implanted into the patient's abdominal sheath to elicit an immune response, and (iv) explantation of the chambers 48 hours later. The clinical trial was open at 32 sites in the United States, and eligible subjects were randomized in a 2:1 ratio to receive bio-di

SUBMITTER: Wong ET 

PROVIDER: S-EPMC11959700 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature